Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium (99mTc) evuzamitide
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
AT-05 (technetium (99mTc) evuzamitide) is an investigational single-photon emission computed tomography (SPECT) radiotracer designed for the non-invasive diagnosis of systemic amyloidosis, particularly cardiac amyloidosis. It consists of a synthetic, polybasic 45-amino-acid pan-amyloid-reactive peptide (p5+14) labeled with the radionuclide technetium-99m. Unlike traditional bone-seeking tracers like technetium-99m pyrophosphate (99mTc-PYP), which selectively detect transthyretin amyloidosis (ATTR), AT-05 binds to hypersulfated heparan sulfate proteoglycans and amyloid fibrils across multiple precursor protein types, enabling the detection of both ATTR and light-chain (AL) amyloidosis. Originally developed by Attralus and the University of Tennessee, the imaging agent was acquired by Bayer in January 2026 and is currently in Phase I clinical development.
- Other names
- 99mTc-evuzamitide99mTc-p5+1499tc-evuzamitidePAR-peptide + technetium-99mTc-99m p5+14Tc-p5+14technetium Tc 99m evuzamitidetechnetium-99m evuzamitidetechnetium99m evuzamitidetechnetium 99m evuzamitide
02
Targets
HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))Aβ (Amyloid-beta peptides and aggregates)Gag (HIV-1 Gag polyprotein)
Beyond the preview
Go deeper on technetium (99mTc) evuzamitide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium (99mTc) evuzamitide.